Outcomes of pharmacological management of nocturia with non-antidiuretic agents: Does statistically significant equal clinically significant?

BJU International

Volumn 107, Issue 10, 2011, Pages 1550-1554

  Smith, Ariana L ^a   Wein, Alan J ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

5 alpha reductase inhibitors; alpha blockers; antimuscarinics; benign prostatic hyperplasia; nocturia; overactive bladder

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DICLOFENAC; DOXAZOSIN; FESOTERODINE; FINASTERIDE; MUSCARINIC RECEPTOR BLOCKING AGENT; NAPROXEN; OXAZEPAM; OXYBUTYNIN; OXYCODONE; PLACEBO; SOLIFENACIN; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN; TOLTERODINE; ZOPICLONE;

ARTICLE; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; EVENING DOSAGE; HUMAN; NOCTURIA; OUTCOME ASSESSMENT; OVERACTIVE BLADDER; PELVIC FLOOR MUSCLE TRAINING; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; SYMPTOMATOLOGY; TREATMENT PLANNING; URINARY URGENCY; URINE INCONTINENCE;

5-ALPHA REDUCTASE INHIBITORS; ADRENERGIC ALPHA-ANTAGONISTS; AGED; DRUG THERAPY, COMBINATION; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; NOCTURIA; PROSTATIC HYPERPLASIA; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE;

EID: 79955386582     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09972.x     Document Type: Article

References (21)

1. Staskin DR, Kelleher C, Bosch R, et al,. Initial assessment of urinary and faecal incontinence in adult male and female patients. In, Abrams P, Cardozo L, Khoury S, Wein AJ, eds. Incontinence, 4th edn. Paris: Health Publications Ltd, 2009: 331-412
2. Asplund R,. Nocturia: consequences for sleep and daytime activities and associated risks. Eur Urol Suppl 2005; 3: 24
3. Coyne KS, Bhattacharyya SK, Thompson CL, Dhawan R, Versi E,. The prevalence of nocturia and its effect on health-related quality of life and sleep in a community sample in the USA. BJU Int 2003; 92: 948-54 (Pubitemid 37548272)
4. Speakman M,. Efficacy and safety of tamsulosin OCAS. BJU Int 2006; 98 (Suppl. 2): 13-7 (Pubitemid 44423031)
5. Johnson TM II, Jones K, Williford WO, Kutner MH, Issa MM, Lepor H,. Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the department of veterans affairs cooperative study trial. J Urol 2003; 170: 145-8 (Pubitemid 36734437)
6. Johnson TM II, Burrows PK, Kusek JW, et al,. The effect of doxazosin, finasteride and combination therapy on nocturia in men with benign prostatic hyperplasia. J Urol 2007; 178: 2045-51 (Pubitemid 47538592)
7. Roehrborn CG, Van Kerrebroeck P, Nordling J,. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int 2003; 92: 257-61 (Pubitemid 36966589)
8. Koseoglu H, Aslan G, Ozdemir I, Esen A,. Nocturnal polyuria in patients with lower urinary tract symptoms and response to alpha-blocker therapy. Urology 2006; 67: 1188-92 (Pubitemid 43818069)
9. Ukimura O, Kanazawa M, Fujihara A, Kamoi K, Okihara K, Miki T, Kyoto Prefectural University of Medicine Benign Prostatic Hypertrophy Research Group. Naftopidil versus tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia with special reference to the storage symptom: a prospective randomized controlled study. Int J Urol 2008; 15: 1049-54
10. Brubaker L, FitzGerald MP,. Nocturnal polyuria and nocturia relief in patients treated with solifenacin for overactive bladder symptoms. Int Urogynecol J Pelvic Floor Dysfunct 2007; 18: 737-41 (Pubitemid 47023322)
11. Cardozo L, Lisec M, Millard R, et al,. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004; 172: 1919-24 (Pubitemid 39363090)
12. Chapple CR, Martinez-Garcia R, Selvaggi L, et al,. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR Trial. Eur Urol 2005; 48: 464-70 (Pubitemid 41188406)
13. Vardy MD, Mitcheson HD, Samuels T-A, et al,. Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT-a double-blind, placebo-controlled trial. Int J Clin Pract 2009; 63: 1702-14
14. Chapple C, Van Kerrebroeck P, Tubaro A, et al,. Clinical efficacy, safety and tolerability of once daily fesoterodine in subjects with overactive bladder. Eur Urol 2007; 52: 1204-12 (Pubitemid 47332062)
15. Dmochowski RR, Peters KM, Morrow JD, et al,. Randomized, double-blind. placebo-controlled trial of flexible dose fesoterodine in subjects with overactive bladder. Urology 2010; 75: 62-8
16. Johnson TM II, Burgio KL, Redden DT, Wright KC, Goode PS,. Effects of behavioral and drug therapy on nocturia in older incontinent women. J Am Geriatr Soc 2005; 53: 846-50 (Pubitemid 41656931)
17. Rackley R, Weiss JP, Rovner ES, Wang JT, Guan Z, 037 STUDY GROUP. Nighttime dosing with tolterodine reduces bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Urology 2006; 67: 731-6
18. Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z,. Tolterodine and Tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder. A Randomized Controlled Trial. JAMA 2006; 296: 2319-28 (Pubitemid 44749359)
19. Vaughan CP, Endeshaw Y, Nagamia Z, Ouslander JG, Johnson TM,. A multicomponent behavioural and drug intervention for nocturia in elderly men: rationale and pilot results. BJU Int 2009; 104: 69-74
20. Addla SK, Adeyoju AB, Neilson D, O'Reilly P,. Diclofenac for treatment of nocturia caused by nocturnal polyuria: a prospective, randomised, double-blind, placebo-controlled crossover study. Eur Urol 2006; 49: 720-5 (Pubitemid 43374738)
21. Kaye M,. Nocturia: a blinded, randomized, parallel placebo-controlled self-study of the effect of 5 different sedatives and analgesics. Can Urol Assoc J 2008; 2: 604-8